Arthroplasty is a orthopaedic surgery procedure, in which the arthritic or dysfunctional joint surface is replaced with something better or by remodeling or realigning the joint by osteotomy or some other procedure. Previously, a popular form of arthroplasty was interpositional arthroplasty with interposition of some other tissue like skin, muscle or tendon to keep inflammatory surfaces apart or excisional arthroplasty in which the joint surface and bone was removed leaving scar tissue to fill in the gap. Other forms of arthroplasty include resection(al) arthroplasty, resurfacing arthroplasty, mold arthroplasty, cup arthroplasty, silicone replacement arthroplasty, etc. Osteotomy to restore or modify joint congruity is also an arthroplasty.
MAKO Surgical Corp., a medical device company that markets both its RIO® Robotic Arm Interactive Orthopedic surgical platform and proprietary RESTORIS® implants for minimally invasive orthopedic knee procedures known as MAKOplasty®, today announced its operating results for its second quarter ended June 30, 2010.
A Mount Sinai School of Medicine study has found that patients often exhibit a significant decrease in weight and body mass index (BMI) after undergoing knee or hip replacement surgery (arthroplasty). The study is the first of its type to correct for the annual increase in BMI typically found in North Americans between the ages of 29 to 73 years. The study was recently published in Orthopedics.
Surgical patients who participate in longer- to 30-minute- discussions prior to having an operation (known as the informed consent process) better understand the proposed operation, according to new research published in the June issue of the Journal of the American College of Surgeons. In addition, researchers found that asking the patient to "repeat back" their understanding of the procedure was effective in enhancing patient comprehension of informed consent issues. This is the largest study ever conducted on the surgical informed consent process.
Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces the first implantation of the PyroTITAN™ Humeral Resurfacing Arthroplasty outside the United States. The PyroTITAN was implanted last month in Brisbane, Australia in a 46-year-old patient who reported "immediate pain relief" within 24 hours of surgery. The PyroTITAN Humeral Resurfacing implant is the first commercially-available shoulder arthroplasty prosthesis made of PyroCarbon in the world.
Orthopaedic Synergy, Inc., is pleased to announce that our acquisition of PRAXIM, SA, Grenoble, France was successfully completed on May 18, 2010.
Eighteen years ago, orthopedic surgeon William Bargar, M.D. made history when, at Sutter General Hospital in Sacramento, he performed the first-ever hip replacement using a robotic device he developed called ROBODOC®, which improves precision in joint replacement surgery. Warren Roberts of Davis was among Dr. Bargar's first patients; in 1995, he underwent replacement of his left hip as a part of an FDA study using ROBODOC®.
Millennium Research Group (MRG), the global authority on medical technology market intelligence, finds that 25% of the 150 orthopedic surgeons surveyed in its newest Physician Forum publication plan to reduce their usage of metal-on-metal hip implants over the next twelve months.
The American College of Occupational and Environmental Medicine today published new medical treatment guidelines for providing care to workers with injuries and disorders of the hip and groin. The new guidelines, which represent the latest chapter in ACOEM's comprehensive publication Occupational Medicine Practice Guidelines, are available on line now via ACOEM's APG-I web application; a print version will be available in the fall of 2010, when the Third Edition hard-copy of Occupational Medicine Practice Guidelines is published.
Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.
The use of statins - drugs commonly prescribed to help lower cholesterol levels - may play an important role in decreasing complications among patients undergoing total hip replacement (THR), according to a study published in the May 2010 issue of the Journal of Bone and Joint Surgery (JBJS).
The joint replacement market in South Africa is set to experience continued growth in the medium to long term, driven by an ageing population that is prone to cartilage degeneration and bone fractures. The introduction of innovative products with enhanced durability and longevity as well as safer operation techniques is further boosting growth in this market.
SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint today announced that iFuse initial post-market clinical experience will be presented at upcoming 2010 minimally invasive spine surgery meetings.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.
Facet Solutions, Inc. today announced that it has finished compiling two year data from its lumbar stenosis pilot study in the US. At two years, patients in the ACADIA™ study experienced significant and sustained improvement in Oswestry Disability Index, VAS back pain and VAS leg pain. There were no re-operations in any of the patients, and all patients met the definition of success for ODI improvement.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.
Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
LDR, a privately held company with innovative spinal implants for non-fusion and fusion applications, announced completion of the 24-month follow-up phase of its two-level IDE study on the Mobi-C cervical artificial disc. Having previously finalized the 24-month follow-up phase of the one-level study earlier this year, LDR is now the first company to fully enroll and reach two-year follow-up on a concurrent one-level and two-level cervical artificial disc replacement study.
ConforMIS, Inc. announced today that the iUni® G2 has received CE Mark certification, providing regulatory approval for ConforMIS to begin the sale of this products throughout the European Union. The iUni G2 is the next generation of ConforMIS' revolutionary patient-specific knee replacement system, and remains the only patient-specific unicompartmental knee resurfacing implant on the market.
Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced the Company received clearance from the Food and Drug Administration (FDA) to market its proprietary BOSS™ bipolar sintered steel coagulation device. The BOSS™ is the latest device based on Bovie’s saline enhanced sintered steel technology.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.